Skip to main content

Table 1 Baseline characteristics of biologic-naïve and TNFi-exposed participants

From: Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

  Biologic naïve (N = 574) TNFi-exposed (N = 2451) p-value
n % n %
Female, n (%) 402 70 1810 73.9 0.06
Rheumatoid factor positive (n = 444:1925) 386 84.9 1625 82 0.012
Cyclic citrullinated peptide (CCP) + ve (n = 13:109) 10 76.9 74 67.9 0.51
No. of prior DMARDs      < 0.001
 None 31 5.4 200 8.2  
 1 95 16.6 53 2.2  
 2 154 26.5 132 5.4  
 3 115 20 408 16.7  
 4 92 16 628 25.6  
 5 59 10.3 583 23.8  
 6–10 28 4.9 447 18.2  
Ever used methotrexate 493 85.9 2185 89.2 0.03
Ever used prednisolone 318 55.4 1933 78.9 < 0.001
Current smoker 78 13.6 341 14.1 0.76
Prior malignancy 44 7.4 94 3.7 < 0.001
  N Mean SD N Mean SD p-value
Age (years) 574 62.4 12.3 2451 55.7 12.4 < 0.001
HAQ (Range 0–3) 572 1.1 0.7 2443 1.2 0.7 < 0.001
AQoL (Range − 0.04 – 1) 572 0.6 0.3 2438 0.5 0.2 < 0.001
EQ5D (UK) (Range − 0.59 - 1) 560 0.7 0.3 2405 0.6 0.3 < 0.001
PCS (Range 0–100) 556 35.1 11.2 2374 32.1 11 < 0.001
MCS (Range 0–100) 556 48.3 11.6 2374 46.5 11.9 0.001
ESR (Range 2–109) 150 26.3 22.1 1259 33.2 25.1 0.002
CRP (Range 0.4–128) 155 17.1 22.6 1260 25.3 30.1 0.001
Joint count (Range 0–50) 150 12.2 12.8 1323 23.5 11 0.001
Years since RA diagnosis 566 13.8 11.6 2444 14.1 10.6 0.1